ACC 2023 – Esperion’s outcomes win looks lacklustre

Data presented at ACC and simultaneously published in the NEJM show a 13% reduction in the risk of major cardiovascular adverse events (Mace) in patients receiving Nexletol versus those on placebo, a result described in an accompanying editorial as “compelling”. However, some had hoped for more.